Skip to content
value.today

DexCare, Inc.

🇺🇸 Seattle, Washington, USAHealth CareFounded 2020
Total raised
$67 M
2 rounds on record
Latest round
$47 M
May 2023
First round on record
Mar 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of DexCare, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$13 MIssued in a merger or acquisition$10 to $50 million

DexCare, Inc.: Private sale, Aug 2026

Investors in this round

14 investors had bought by the notice of Sep 14, 2026: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $23 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Blosl · Executive Officer, Director
  • Branden Fini · Director
  • Caroline Xie · Director
  • Lynne Chou O'Keefe · Director
  • Paul Minardi · Director
  • Toby Cosgrove · Director
  • Todd Cozzens · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Blosl, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 14, 2026. Read the notice at the SEC.

equitySEC
May 2023$47 MNo. 2$10 to $50 million

DexCare, Inc.: Raise no. 2, May 2023

Investors in this round

10 investors had bought by the notice of Jun 27, 2023: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$47 M of $60 M offered; $13 M still to sell
Smallest investment taken
$14,149,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Streat · Executive Officer, Director
  • Caroline Chou Xie · Director
  • David Kereiakes · Director
  • Delos Chou Cosgrove · Director
  • Lynne Chou O'Keefe · Director
  • Todd Chou Cozzens · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daren Nitz, Counsel. Source: SEC Form D, newest notice filed Jun 27, 2023. Read the notice at the SEC.

equitySEC
Mar 2021$20 MNo. 1$10 to $50 million

DexCare, Inc.: Raise no. 1, Mar 2021

Investors in this round

11 investors had bought by the notice of Mar 10, 2021: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
$49,999
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Derek Streat · Executive Officer, Director
  • Aaron Martin · Director
  • Lynne Chou O?Keefe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daren Nitz, Counsel. Source: SEC Form D, newest notice filed Mar 10, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • DexCare, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2026

That is all the official record says: DexCare, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of DexCare, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by DexCare, Inc.
NameRoleNamed in
Matthew BloslExecutive officerSep 2026
Derek StreatExecutive officerJun 2023
Branden FiniDirectorSep 2026
Caroline XieDirectorSep 2026
Lynne Chou O'KeefeDirectorSep 2026
Matthew BloslDirectorSep 2026
Paul MinardiDirectorSep 2026
Toby CosgroveDirectorSep 2026
Todd CozzensDirectorSep 2026
Caroline Chou XieDirectorJun 2023
David KereiakesDirectorJun 2023
Delos Chou CosgroveDirectorJun 2023
Derek StreatDirectorJun 2023
Todd Chou CozzensDirectorJun 2023
Aaron MartinDirectorMar 2021
Lynne Chou O?KeefeDirectorMar 2021